Image

Effect of PPV+ILM Peeling +/- Subretinal Injection of Ringer Lactate in Management of Nontractional Refractory DME

Recruiting
40 - 80 years of age
Both
Phase N/A

Powered by AI

Overview

To evaluate the efficacy and safety of combined pars plana vitrectomy and planned foveal detachment through subretinal injection of ringer's solution in patients with non-tractional refractory diabetic macular edema.

Description

In non-tractional cases, PPV allows a more efficient clearance of VEGF and other cytokines from the retina and improves retinal oxygenation by promotion of intraocular fluid currents, and relief of any subclinical tractional forces, thereby reducing DME.

To evaluate the efficacy and safety of combined pars plana vitrectomy and planned foveal detachment through subretinal injection of ringer's solution in patients with non-tractional refractory diabetic macular edema.

Eligibility

Inclusion Criteria:

  • Age: above 40 years old.
    • Patients with type two diabetes mellitus of more than 5 years duration.
    • Patients with Best corrected visual acuity better than 3/60.
    • Central macular thickness (CMT) of more than 250 μm despite undergoing six monthly injection of anti-VEGF therapy or corticosteroid or less than 10% reduction in CMT at the last follow up visit.
    • No evidence of vitreomacular traction.
    • Lens status: Pseudophakia or clear crystalline lens.

Exclusion Criteria:

        Other causes of macular edema (intraocular inflammation, retinal vein occlusion, Irvin-gass
        syndrome, pharmacological).
          -  Ischemic maculopathy by FFA.
          -  Presence of bad prognostic signs in OCT such as disorganization of inner retinal
             layers (DRIL) and extensive disruption of IS-OS junction subfoveally.
          -  Presence of apparent retinal pigment epithelium (RPE) atrophy at or near the macula.
          -  Presence of proliferative diabetic fibrovascular membranes threatening or at the
             macula.
          -  Presence of diabetic optic atrophy or neuropathy.
          -  Presence of neovascular glaucoma.
          -  Cataractous lens either preoperatively or as intra or postoperative complication.
          -  Vitrectomized Eyes.
          -  A prior intraocular surgery within the past six-months.
          -  Lost follow up

Study details

Efficacy, Safety

NCT06271473

Ain Shams University

7 March 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.